← Back to Search

Digital Health Platform for Prostate Cancer

N/A

Recruiting

Led By Hala Borno, MD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >18 years

Ability of individual or legal guardian/representative to understand an informed consent document and the willingness to sign it

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 months

Awards & highlights

Study Summary

This trial studies a digital platform, STAND-T, that provides information and resources to help improve health and address symptoms in men with prostate cancer.

Who is the study for?

This trial is for men over 18 with prostate cancer who are on or planning to start anti-androgen therapy. They should have a life expectancy of at least 6 months, understand the study and consent to participate. Men who exercise very little and haven't had recent dietary or exercise counseling can join.Check my eligibility

What is being tested?

The STAND-T digital platform is being tested in this trial. It's designed to provide health information and resources specifically for men undergoing androgen deprivation therapy for prostate cancer, aiming to improve their health outcomes and promote equity.See study design

What are the potential side effects?

Since the intervention involves a digital platform providing information rather than a medical treatment, traditional side effects like those seen with medications are not expected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I can understand and am willing to sign the informed consent document.

Select...

I have been diagnosed with prostate adenocarcinoma.

Select...

I am currently on or planning to start hormone therapy for cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Completion rate

Secondary outcome measures

Change in the proportion of men who were Extremely Satisfied/Satisfied

Participants reported satisfaction level

Trial Design

1Treatment groups

Experimental Treatment

Group I: Health services research (STAND-T, text messages)Experimental Treatment3 Interventions

Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor

2,506 Previous Clinical Trials

15,238,505 Total Patients Enrolled

51 Trials studying Prostate Cancer

16,983 Patients Enrolled for Prostate Cancer

Myovant Sciences GmbHIndustry Sponsor

22 Previous Clinical Trials

12,440 Total Patients Enrolled

5 Trials studying Prostate Cancer

4,594 Patients Enrolled for Prostate Cancer

Hala Borno, MDPrincipal InvestigatorUniversity of California, San Francisco

2 Previous Clinical Trials

262 Total Patients Enrolled

1 Trials studying Prostate Cancer

10 Patients Enrolled for Prostate Cancer

Media Library

STAND-T platform Clinical Trial Eligibility Overview. Trial Name: NCT05324098 — N/A

Prostate Cancer Research Study Groups: Health services research (STAND-T, text messages)

Prostate Cancer Clinical Trial 2023: STAND-T platform Highlights & Side Effects. Trial Name: NCT05324098 — N/A

STAND-T platform 2023 Treatment Timeline for Medical Study. Trial Name: NCT05324098 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being recruited for this investigation?

"According to clinicaltrials.gov, this medical experiment is enlisting participants at the current time. This trial was first introduced on March 8th 2022 and has been modified as recently as October 26th of that same year."

Answered by AI

What is the size of the population under examination in this research?

"Affirmative. According to information hosted on clinicaltrials.gov, this medical trial is now enrolling candidates with 50 participants required across two sites. The study was first posted on March 8th 2022 and has been recently revisited October 26th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy

2022. "Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05324098.